Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidom

Trial Details

NCT ID

NCT02343042

Phase

PHASE1 / PHASE2

Sponsor

Karyopharm Therapeutics Inc

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Selinexor
Dexamethasone
Lenalidomide
Pomalidomide
Bortezomib
Daratumumab

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Los Angeles, California, United States|34.05223,-118.24368
Denver, Colorado, United States|39.73915,-104.9847
Boston, Massachusetts, United States|42.35843,-71.05977
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Written informed consent signed in accordance with federal, local, and institutional guidelines.
Age greater than or equal to (≥) 18 years at the time of informed consent.
Histologically confirmed diagnosis with measurable disease for relapsed/refractory myeloma.
Symptomatic MM, based on IMWG guidelines.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →